NTLA: Bull Flag detected on 7 Jul 2026

NTLA has formed a bull flag pattern following a sharp rally, consolidating between $16.00 support and $17.18 resistance near the $17.84 level. The structure scores a solid 15.0/15, indicating clean flag geometry, while the 10.5/13 breakout score reflects some caution on follow-through momentum. Volume at 3.8M shares is only 58% of the 20-day average, suggesting the flag is contracting on lighter activity—typical flag behavior. The 83.5/98 overall score and 75.45% win probability indicate a high-probability setup, though the RSI at 70.63 signals overbought conditions that warrant attention.

Intellia Therapeutics is a clinical-stage CRISPR gene-editing company focused on in vivo therapeutics. Recent biotech sector strength has lifted NTLA 37% in one month and 124% from its 52-week low, outpacing the broader Healthcare regime (bullish at 0.87). The stock trades 36.85% below its 52-week high, indicating room for recovery. A beta of 1.41 amplifies both upside and downside moves typical of early-stage biotech. No major earnings catalysts or regulatory announcements were identified in recent news cycle, suggesting the current rally is driven by sector tailwinds and positive momentum rather than company-specific news. The pattern formed during a period of broad biotech optimism.

A successful breakout above $17.18 resistance would target $18.43 (the conservative measured move), representing a 3.3% gain from current price. Volume confirmation is critical—the flag's breakout needs to exceed the 6.65M share 20-day average to validate the move, as current volume of 3.8M is notably weak. The pattern invalidates decisively below the $16.00 support level, where the flag's lower trendline anchors. Historical bull flag data supports the 75.45% win probability, but overbought RSI conditions suggest breakout confirmation must be clean and volume-supported to avoid a false breakout or pullback.

RSI at 70.63 indicates overbought conditions—a significant red flag in early-stage biotech stocks prone to sharp reversals. The stock is 36.85% below its 52-week high, suggesting distribution pressure at higher levels. Volume has dried up to only 58% of average, indicating weak participation that could evaporate on a failed breakout. Beta of 1.41 magnifies downside risk in a sector correction. Biotech sector volatility at 0.9802 (98% annualized) is elevated, and NTLA's 7.51% ATR as a percentage of price reflects high intraday swings. No identified near-term catalysts exist, meaning the setup relies entirely on technical momentum—a vulnerable position if sentiment shifts. Early-stage biotech is vulnerable to clinical trial delays, regulatory setbacks, or capital market conditions deteriorating.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.